Prohemostatic Treatment in Cardiac Surgery

Jerrold H. Levy; Roman M. Sniecinski

doi:10.1055/s-0032-1304223

Seminars in Thrombosis and Hemostasis, Table of Contents

Semin Thromb Hemost 2012; 38(03): 237-243
DOI: 10.1055/s-0032-1304223

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Prohemostatic Treatment in Cardiac Surgery

Jerrold H. Levy

¹Department of Anesthesiology, Emory University School of Medicine and Emory Healthcare, Atlanta, Georgia

,

Roman M. Sniecinski

²Department of Anesthesiology, Emory University School of Medicine and Emory Healthcare, Atlanta, Georgia

› Author Affiliations

Abstract

Cardiac surgical patients represent a unique group of patients where coagulopathy occurs due to multiple causes besides simple hemorrhagic blood loss. Hemodilution, inflammation, and hemostatic activation while on cardiopulmonary bypass all contribute to this problem and provide targets for therapeutic intervention. Current pharmacological strategies to reduce the need for allogeneic transfusions include both preemptive agents to decrease the potential for bleeding as well as prohemostatic agents to promote the coagulation process. This article will discuss pharmacological agents including antifibrinolytics, protamine, desmopressin, fibrinogen, purified protein concentrates, recombinant factor VIIa, factor XIII, and topical agents used in cardiac surgery.

Keywords

antifibrinolytics - protamine - desmopressin - fibrinogen - purified protein concentrates - recombinant factor VIIa - factor XIII

Full Text

References

References
1 Mannucci PM, Levi M. Prevention and treatment of major blood loss. N Engl J Med 2007; 356 (22) 2301-2311
2 Hein OV, Birnbaum J, Wernecke KD, Konertz W, Jain U, Spies C. Three-year survival after four major post-cardiac operative complications. Crit Care Med 2006; 34 (11) 2729-2737
3 Christensen MC, Krapf S, Kempel A, von Heymann C. Costs of excessive postoperative hemorrhage in cardiac surgery. J Thorac Cardiovasc Surg 2009; 138 (3) 687-693
4 Karkouti K, Wijeysundera DN, Beattie WS , et al; Reducing Bleeding in Cardiac Surgery (RBC) Research Group. Variability and predictability of large-volume red blood cell transfusion in cardiac surgery: a multicenter study. Transfusion 2007; 47 (11) 2081-2088
5 Sniecinski RM, Levy JH. Bleeding and management of coagulopathy. J Thorac Cardiovasc Surg 2011; 142 (3) 662-667
6 Edmunds Jr LH. Managing fibrinolysis without aprotinin. Ann Thorac Surg 2010; 89 (1) 324-331
7 Spiess BD, Royston D, Levy JH , et al. Platelet transfusions during coronary artery bypass graft surgery are associated with serious adverse outcomes. Transfusion 2004; 44 (8) 1143-1148
8 Spiess BD. Risks of transfusion: outcome focus. Transfusion 2004; 44 (12, Suppl) 4S-14S
9 Spiess BD. Transfusion of blood products affects outcome in cardiac surgery. Semin Cardiothorac Vasc Anesth 2004; 8 (4) 267-281
10 Levy JH. Massive transfusion coagulopathy. Semin Hematol 2006; 43 (1, Suppl 1) S59-S63
11 Royston D, Chhatwani A. Safety aspects of aprotinin therapy in cardiac surgery patients. Expert Opin Drug Saf 2006; 5 (4) 539-552
12 Levi M, Cromheecke ME, de Jonge E , et al. Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints. Lancet 1999; 354 (9194) 1940-1947
13 Sedrakyan A, Treasure T, Elefteriades JA. Effect of aprotinin on clinical outcomes in coronary artery bypass graft surgery: a systematic review and meta-analysis of randomized clinical trials. J Thorac Cardiovasc Surg 2004; 128 (3) 442-448
14 Mangano DT, Tudor IC, Dietzel C ; Multicenter Study of Perioperative Ischemia Research Group; Ischemia Research and Education Foundation. The risk associated with aprotinin in cardiac surgery. N Engl J Med 2006; 354 (4) 353-365
15 Mangano DT, Miao Y, Vuylsteke A , et al; Investigators of The Multicenter Study of Perioperative Ischemia Research Group; Ischemia Research and Education Foundation. Mortality associated with aprotinin during 5 years following coronary artery bypass graft surgery. JAMA 2007; 297 (5) 471-479
16 Fergusson DA, Hébert PC, Mazer CD , et al; BART Investigators. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med 2008; 358 (22) 2319-2331
17 FDA. Available at: http://www.fda.gov/bbs/topics/NEWS/2008/NEW01834.html 2008
18 Karkouti K, Wijeysundera DN, Yau TM, McCluskey SA, Tait G, Beattie WS. The risk-benefit profile of aprotinin versus tranexamic acid in cardiac surgery. Anesth Analg 2010; 110 (1) 21-29
19 Henry D, Carless P, Fergusson D, Laupacis A. The safety of aprotinin and lysine-derived antifibrinolytic drugs in cardiac surgery: a meta-analysis. CMAJ 2009; 180 (2) 183-193
20 Martin K, Wiesner G, Breuer T, Lange R, Tassani P. The risks of aprotinin and tranexamic acid in cardiac surgery: a one-year follow-up of 1188 consecutive patients. Anesth Analg 2008; 107 (6) 1783-1790
21 Murkin JM, Falter F, Granton J, Young B, Burt C, Chu M. High-dose tranexamic Acid is associated with nonischemic clinical seizures in cardiac surgical patients. Anesth Analg 2010; 110 (2) 350-353
22 Levy JH, Adkinson Jr NF. Anaphylaxis during cardiac surgery: implications for clinicans. Anesth Analg 2008; 106 (2) 392-403
23 Mochizuki T, Olson PJ, Szlam F, Ramsay JG, Levy JH. Protamine reversal of heparin affects platelet aggregation and activated clotting time after cardiopulmonary bypass. Anesth Analg 1998; 87 (4) 781-785
24 Kuitunen AH, Salmenperä MT, Heinonen J, Rasi VP, Myllylä G. Heparin rebound: a comparative study of protamine chloride and protamine sulfate in patients undergoing coronary artery bypass surgery. J Cardiothorac Vasc Anesth 1991; 5 (3) 221-226
25 Mittermayr M, Velik-Salchner C, Stalzer B , et al. Detection of protamine and heparin after termination of cardiopulmonary bypass by thrombelastometry (ROTEM): results of a pilot study. Anesth Analg 2009; 108 (3) 743-750
26 Mannucci PM. Treatment of von Willebrand's disease. N Engl J Med 2004; 351 (7) 683-694
27 Mannucci PM. Hemostatic drugs. N Engl J Med 1998; 339 (4) 245-253
28 Mannucci PM. Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years. Blood 1997; 90 (7) 2515-2521
29 Federici AB, Mannucci PM. Management of inherited von Willebrand disease in 2007. Ann Med 2007; 39 (5) 346-358
30 Frankville DD, Harper GB, Lake CL, Johns RA. Hemodynamic consequences of desmopressin administration after cardiopulmonary bypass. Anesthesiology 1991; 74 (6) 988-996
31 Rocha E, Llorens R, Páramo JA, Arcas R, Cuesta B, Trenor AM. Does desmopressin acetate reduce blood loss after surgery in patients on cardiopulmonary bypass?. Circulation 1988; 77 (6) 1319-1323
32 Salzman EW, Weinstein MJ, Reilly D, Ware JA. Adventures in hemostasis. Desmopressin in cardiac surgery. Arch Surg 1993; 128 (2) 212-217
33 Salzman EW, Weinstein MJ, Weintraub RM , et al. Treatment with desmopressin acetate to reduce blood loss after cardiac surgery. A double-blind randomized trial. N Engl J Med 1986; 314 (22) 1402-1406
34 Weinstein M, Ware JA, Troll J, Salzman E. Changes in von Willebrand factor during cardiac surgery: effect of desmopressin acetate. Blood 1988; 71 (6) 1648-1655
35 de Prost D, Barbier-Boehm G, Hazebroucq J , et al. Desmopressin has no beneficial effect on excessive postoperative bleeding or blood product requirements associated with cardiopulmonary bypass. Thromb Haemost 1992; 68 (2) 106-110
36 Mannucci PM, Carlsson S, Harris AS. Desmopressin, surgery and thrombosis. Thromb Haemost 1994; 71 (1) 154-155
37 Nielsen VG, Levy JH. Fibrinogen and bleeding: old molecule—new ideas. Anesth Analg 2007; 105 (4) 902-903
38 Levy JH, Szlam F, Tanaka KA. Sniecienski MG: Fibrinogen and hemostasis: a primary hemostatic target for the management of acquired bleeding. Anesth Analg 2012; 114: 261-274
39 Blome M, Isgro F, Kiessling AH , et al. Relationship between factor XIII activity, fibrinogen, haemostasis screening tests and postoperative bleeding in cardiopulmonary bypass surgery. Thromb Haemost 2005; 93 (6) 1101-1107
40 Charbit B, Mandelbrot L, Samain E , et al; PPH Study Group. The decrease of fibrinogen is an early predictor of the severity of postpartum hemorrhage. J Thromb Haemost 2007; 5 (2) 266-273
41 Karlsson M, Ternström L, Hyllner M , et al. Prophylactic fibrinogen infusion reduces bleeding after coronary artery bypass surgery. A prospective randomised pilot study. Thromb Haemost 2009; 102 (1) 137-144
42 Karlsson M, Ternström L, Hyllner M, Baghaei F, Nilsson S, Jeppsson A. Plasma fibrinogen level, bleeding, and transfusion after on-pump coronary artery bypass grafting surgery: a prospective observational study. Transfusion 2008; 48 (10) 2152-2158
43 O'Shaughnessy DF, Atterbury C, Bolton Maggs P , et al; British Committee for Standards in Haematology, Blood Transfusion Task Force. Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. Br J Haematol 2004; 126 (1) 11-28
44 Pipe SW. Recombinant clotting factors. Thromb Haemost 2008; 99 (5) 840-850
45 Levy JH, Levi M. A modified recombinant factor VIIa: can we make it work harder, better, faster, stronger?. J Thromb Haemost 2009; 7 (9) 1514-1516
46 Steiner ME, Key NS, Levy JH. Activated recombinant factor VII in cardiac surgery. Curr Opin Anaesthesiol 2005; 18 (1) 89-92
47 Hoffman M, Monroe III DM. A cell-based model of hemostasis. Thromb Haemost 2001; 85 (6) 958-965
48 Goodnough LT, Lublin DM, Zhang L, Despotis G, Eby C. Transfusion medicine service policies for recombinant factor VIIa administration. Transfusion 2004; 44 (9) 1325-1331
49 Despotis G, Avidan M, Lublin DM. Off-label use of recombinant factor VIIA concentrates after cardiac surgery. Ann Thorac Surg 2005; 80 (1) 3-5
50 Levy JH, Fingerhut A, Brott T, Langbakke IH, Erhardtsen E, Porte RJ. Recombinant factor VIIa in patients with coagulopathy secondary to anticoagulant therapy, cirrhosis, or severe traumatic injury: review of safety profile. Transfusion 2006; 46 (6) 919-933
51 Gill R, Herbertson M, Vuylsteke A , et al. Safety and efficacy of recombinant activated factor VII: a randomized placebo-controlled trial in the setting of bleeding after cardiac surgery. Circulation 2009; 120 (1) 21-27
52 Furnary AP, Wu Y, Hiratzka LF, Grunkemeier GL, Page III US. Aprotinin does not increase the risk of renal failure in cardiac surgery patients. Circulation 2007; 116 (11, Suppl) I127-I133
53 Koch CG, Li L, Sessler DI , et al. Duration of red-cell storage and complications after cardiac surgery. N Engl J Med 2008; 358 (12) 1229-1239
54 O'Connell KA, Wood JJ, Wise RP, Lozier JN, Braun MM. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA 2006; 295 (3) 293-298
55 Levi M, Levy JH, Andersen HF, Truloff D. Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med 2010; 363 (19) 1791-1800
56 Levy JH, Gill R, Nussmeier NA , et al. Repletion of factor XIII following cardiopulmonary bypass using a recombinant A-subunit homodimer. A preliminary report. Thromb Haemost 2009; 102 (4) 765-771
57 Gödje O, Gallmeier U, Schelian M, Grünewald M, Mair H. Coagulation factor XIII reduces postoperative bleeding after coronary surgery with extracorporeal circulation. Thorac Cardiovasc Surg 2006; 54 (1) 26-33
58 Gödje O, Haushofer M, Lamm P, Reichart B. The effect of factor XIII on bleeding in coronary surgery. Thorac Cardiovasc Surg 1998; 46 (5) 263-267
59 Levy JH, Tanaka KA, Dietrich W. Perioperative hemostatic management of patients treated with vitamin K antagonists. Anesthesiology 2008; 109 (5) 918-926
60 Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G ; American College of Chest Physicians. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 160S-198S
61 Lankiewicz MW, Hays J, Friedman KD, Tinkoff G, Blatt PM. Urgent reversal of warfarin with prothrombin complex concentrate. J Thromb Haemost 2006; 4 (5) 967-970
62 Kessler CM. Urgent reversal of warfarin with prothrombin complex concentrate: where are the evidence-based data?. J Thromb Haemost 2006; 4 (5) 963-966
63 Dickneite G. Prothrombin complex concentrate versus recombinant factor VIIa for reversal of coumarin anticoagulation. Thromb Res 2007; 119 (5) 643-651
64 Achneck HE, Sileshi B, Jamiolkowski RM, Albala DM, Shapiro ML, Lawson JH. A comprehensive review of topical hemostatic agents: efficacy and recommendations for use. Ann Surg 2010; 251 (2) 217-228
65 Achneck HE, Sileshi B, Jamiolkowski RM, Albala DM, Shapiro ML, Lawson JH. A comprehensive review of topical hemostatic agents: efficacy and recommendations for use. Ann Surg 2010; 251 (2) 217-228
66 Lawson JH. The clinical use and immunologic impact of thrombin in surgery. Semin Thromb Hemost 2006; 32 (Suppl. 01) 98-110